Your browser doesn't support javascript.
loading
Tumor-suppressive miR-4732-3p is sorted into fucosylated exosome by hnRNPK to avoid the inhibition of lung cancer progression.
Zhuang, Wanzhen; Liu, Chengxiu; Hong, Yilin; Zheng, Yue; Huang, Minjian; Tang, Haijun; Zhao, Lilan; Huang, Zhixin; Tu, Mingshu; Yu, Lili; Chen, Jianlin; Zhang, Yi; Chen, Xiongfeng; Lin, Fan; Gao, Qi; Yu, Chundong; Huang, Yi.
Afiliación
  • Zhuang W; Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
  • Liu C; Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • Hong Y; State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, 361102, China.
  • Zheng Y; Institute of Future Technology, Beijing Hotgen Biotech Co., Ltd, Beijing, 102600, China.
  • Huang M; State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, 361102, China.
  • Tang H; Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
  • Zhao L; Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • Huang Z; Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
  • Tu M; Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • Yu L; Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
  • Chen J; Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • Zhang Y; Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
  • Chen X; Department of Thoracic Surgery, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • Lin F; Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • Gao Q; Integrated Chinese and Western Medicine College, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China.
  • Yu C; Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
  • Huang Y; Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, China.
J Exp Clin Cancer Res ; 43(1): 123, 2024 Apr 23.
Article en En | MEDLINE | ID: mdl-38654325
ABSTRACT

BACKGROUND:

Aberrant fucosylation observed in cancer cells contributes to an augmented release of fucosylated exosomes into the bloodstream, where miRNAs including miR-4732-3p hold promise as potential tumor biomarkers in our pilot study. However, the mechanisms underlying the sorting of miR-4732-3p into fucosylated exosomes during lung cancer progression remain poorly understood.

METHODS:

A fucose-captured strategy based on lentil lectin-magnetic beads was utilized to isolate fucosylated exosomes and evaluate the efficiency for capturing tumor-derived exosomes using nanoparticle tracking analysis (NTA). Fluorescence in situ hybridization (FISH) and qRT-PCR were performed to determine the levels of miR-4732-3p in non-small cell lung cancer (NSCLC) tissue samples. A co-culture system was established to assess the release of miRNA via exosomes from NSCLC cells. RNA immunoprecipitation (RIP) and miRNA pull-down were applied to validate the interaction between miR-4732-3p and heterogeneous nuclear ribonucleoprotein K (hnRNPK) protein. Cell functional assays, cell derived xenograft, dual-luciferase reporter experiments, and western blot were applied to examine the effects of miR-4732-3p on MFSD12 and its downstream signaling pathways, and the impact of hnRNPK in NSCLC.

RESULTS:

We enriched exosomes derived from NSCLC cells using the fucose-captured strategy and detected a significant upregulation of miR-4732-3p in fucosylated exosomes present in the serum, while its expression declined in NSCLC tissues. miR-4732-3p functioned as a tumor suppressor in NSCLC by targeting 3'UTR of MFSD12, thereby inhibiting AKT/p21 signaling pathway to induce cell cycle arrest in G2/M phase. NSCLC cells preferentially released miR-4732-3p via exosomes instead of retaining them intracellularly, which was facilitated by the interaction of miR-4732-3p with hnRNPK protein for selective sorting into fucosylated exosomes. Moreover, knockdown of hnRNPK suppressed NSCLC cell proliferation, with the elevated levels of miR-4732-3p in NSCLC tissues but the decreased expression in serum fucosylated exosomes.

CONCLUSIONS:

NSCLC cells escape suppressive effects of miR-4732-3p through hnRNPK-mediated sorting of them into fucosylated exosomes, thus supporting cell malignant properties and promoting NSCLC progression. Our study provides a promising biomarker for NSCLC and opens a novel avenue for NSCLC therapy by targeting hnRNPK to prevent the "exosome escape" of tumor-suppressive miR-4732-3p from NSCLC cells.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Ribonucleoproteína Heterogénea-Nuclear Grupo K / MicroARNs / Exosomas / Fucosa / Neoplasias Pulmonares Límite: Animals / Humans Idioma: En Revista: J Exp Clin Cancer Res Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Ribonucleoproteína Heterogénea-Nuclear Grupo K / MicroARNs / Exosomas / Fucosa / Neoplasias Pulmonares Límite: Animals / Humans Idioma: En Revista: J Exp Clin Cancer Res Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido